Table 1

Baseline demographics and disease severity characteristics for patients originally randomised to CZP at week 0 or re-randomised from placebo at weeks 16 and 24 of the RAPID-PsA study

CZP 200 mg Q2WCZP 400 mg Q4W
Week 0 CZP (n=138)PBO→CZP
week 16 (n=30)
PBO→CZP week 24 (n=30)Week 0 CZP (n=135)PBO→CZP
week 16 (n=29)
PBO→CZP week 24 (n=31)
Demographic characteristics
 Age, years48.2±12.348.0±11.647.8±11.447.1±10.849.3±10.045.0±10.7
 Sex, % female53.656.763.354.165.551.6
 Race, % white97.810010098.596.693.5
 Weight, kg85.8±17.782.8±18.781.1±16.584.8±18.778.9±21.587.3±23.4
 BMI, kg/m230.5±6.228.9±5.528.5±4.129.6±6.628.1±7.030.9±9.3
Arthritis characteristics
 Time from psoriatic arthritis diagnosis,* years9.6±8.57.7±7.37.3±7.58.1±8.310.6±10.36.3±5.7
 CRP† (mg/L), median (minimum–maximum)7.0 (0.3–238.0)6.5 (0.2–100.0)8.7 (0.3–32.3)9.1 (0.1–87.0)10.3 (1.1–80.7)10.3 (0.7–60.0)
 ESR (mm/h), median (minimum–maximum)35.0 (5.0–125.0)32.5 (15–91)32.0 (20–95)33.0 (4.0–120.0)35.0 (10–92)31.0 (6–70)
 Tender joint count (0–68 joints)21.5±15.319.4±15.217.0±13.819.6±14.818.4±11.221.2±16.0
 Swollen joint count (0–66 joints)11.0±8.810.0±7.99.7±7.010.5±7.510.0±6.210.0±7.5
 HAQ-DI (range 0–3)1.3±0.71.3±0.61.2±0.61.3±0.61.5±0.61.1±0.7
 Modified total Sharp score15.4±27.925.3±50.218.5±24.820.9±45.337.0±79.215.5±30.3
  Erosion score9.4±16.215.7±29.610.7±14.012.9±25.321.7±43.39.7±17.4
  Joint space narrowing score6.0±12.49.7±20.97.8±12.08.0±20.515.2±36.25.7±13.5
Psoriasis characteristics
  Psoriasis BSA ≥3%, n (%)90 (65.2)18 (60.0)20 (66.7)76 (56.3)20 (69.0)16 (51.6)
  PASI,‡ median (minimum–maximum)7.0 (0.6–72.0)9.1 (0.5–20.1)4.6 (0.3–20.4)8.1 (0.6–51.8)7.7 (0.6–37.9)6.0 (1.2–36.9)
Prior use of synthetic DMARDs, n (%)
 161 (44.2)17 (56.7)18 (60.0)68 (50.4)11 (37.9)17 (54.8)
 ≥274 (53.6)12 (40.0)12 (40.0)64 (47.4)17 (58.6)14 (45.2)
Concomitant use of NSAIDs to week 96, n (%)106 (76.8)25 (83.3)20 (66.7)105 (77.8)22 (75.9)26 (83.9)
Prior anti-TNF exposure, n (%)31 (22.5)9 (30.0)3 (10.0)23 (17.0)7 (24.1)2 (6.5)
Concomitant use of MTX to week 96, n (%)90 (65.2)18 (60.0)20 (66.7)87 (64.4)19 (65.5)20 (64.5)
  • Data are shown for the Randomised Set. Except where indicated otherwise, values are the mean±SD.

  • *From the start date of primary disease.

  • †Normal range of CRP <8.0 mg/L.

  • ‡PASI scores reported for patients with psoriasis body surface area ≥3% at baseline.

  • BMI, body mass index; BSA, body surface area; CRP, C reactive protein; CZP, certolizumab pegol; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PBO, placebo; Q2W, every 2 weeks; TNF, tumour necrosis factor.